Article
TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study.
Cancer research - 1 Jul 2006
Gormally Emmanuelle, Vineis Paolo, Matullo Giuseppe, Veglia Fabrizio, Caboux Elodie, Le Roux Emilie, Peluso Marco, Garte Seymour, Guarrera Simonetta, Munnia Armelle, Airoldi Luisa, Autrup Herman, Malaveille Christian, Dunning Alison, Overvad Kim, Tjønneland Anne, Lund Eiliv, Clavel-Chapelon Françoise, Boeing Heiner, Trichopoulou Antonia, Palli Domenico, Krogh Vittorio, Tumino Rosario, Panico Salvatore, Bueno-de-Mesquita H Bas, Peeters Petra H, Pera Guillem, Martinez Carmen, Dorronsoro Miren, Barricarte Aurelio, Navarro Carmen, Quirós José Ramón, Hallmans Göran, Day Nicholas E, Key Timothy J, Saracci Rodolfo, Kaaks Rudolf, Riboli Elio, Hainaut Pierre
Abstract excerpt
In cancer patients, plasma often contains mutant DNA released by cancer cells. We have assessed the significance of plasma DNA mutations for subsequent cancer development in healthy subjects in a large longitudinal prospective study. The European Prospective Investigation into Cancer and Nutrition study was analyzed with a nested case-control design. Cases were nonsmokers or ex-smokers for >10 years and newly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.